20
Aug
2019

Getting in on the Ground Floor of the Biotech Boom: Joel Marcus on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Building a Fully Integrated Biopharma For the Muscle: Robert Blum on The Long Run
Looking at Live Cells and How They Interact at Scale: Mostafa Ronaghi on The Long Run
Investing in Biotech: David Schenkein on The Long Run
The Past, Present and Future of RNAi Therapies: Kevin Fitzgerald on The Long Run